Overall survival · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).
1 finding from 1 review
Prevention of acute GVHD grade II to IV · people receiving allogeneic hematopoietic stem cell transplantation
It is very uncertain whether mycophenolate mofetil changes prevention of acute GVHD grade II to IV compared with methotrexate (very low certainty).
1 finding from 1 review
Relapse · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in incidence of relapse compared with methotrexate (low certainty).
1 finding from 1 review
Nonrelapse mortality · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in nonrelapse mortality compared with methotrexate (low certainty).
1 finding from 1 review
Prevention of chronic GVHD · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in prevention of chronic GVHD compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of severe mucositis · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower incidence of severe mucositis compared with methotrexate (low certainty).
1 finding from 1 review
Use of total parenteral nutrition · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower use of total parenteral nutrition compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of narcotic use for pain control · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower incidence of narcotic use for pain control compared with methotrexate (low certainty).
1 finding from 1 review
Safety of MSC infusion · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with best available therapy (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib may leads to higher safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with placebo (low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · Patients with treating MF
Ruxolitinib may leads to higher safety (AE, adverse drug reaction): neutropenia Grades 3 or 4… compared with placebo (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): anemia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): anemia Grades 3 or 4 according… compared with best available therapy (low certainty).
1 finding from 1 review